Search

A study conducted by Johns Hopkins University examined the use of Kratom (Mitragyna speciosa) for self-management of pain in the US. The research found that nearly half of the participants met criteria for chronic pain and reported significant pain relief and effectiveness of Kratom in managing pain. The study highlighted the need for further research on the safety, efficacy, and long-term implications of Kratom for pain management to inform clinical practices and regulatory policies. The findings underscore the common use of Kratom among individuals with chronic pain and its potential benefits in pain self-management. [Extracted from the article]

A recent study from the University of Mississippi found that nearly three-fourths of tobacco and vape stores in the US sell kratom, a substance with potential risks such as liver toxicity, seizures, and death. Despite federal warnings and some state restrictions, kratom remains widely available across the country. The product, marketed as a mood stabilizer and painkiller, has been linked to poisonings and hospitalizations, highlighting the disconnect between its perceived benefits and potential dangers. Researchers emphasize the lack of oversight in kratom production and the need for caution due to its addictive nature and associated health risks. [Extracted from the article]

Many consumers are turning to kratom (Mitragyna speciosa) to self-manage pain and opioid addiction. In the United States, an array of capsules, powders, and loose-leaf kratom products are readily available. Additionally, several online sites supply live kratom plants. A prerequisite to establishing quality control and quality assurance standards for the kratom industry, or understanding how alkaloid levels effect clinical outcomes, is the identification and quantitation of major and minor alkaloid constituents within available products and preparations. To this end, an ultra-high performance liquid chromatography-high resolution mass spectrometry method was developed for the analysis of 8 indole alkaloids (7-hydroxymitragynine, ajmalicine, paynantheine, mitragynine, speciogynine, isopaynantheine, speciociliatine, and mitraciliatine) and 6 oxindole alkaloids (isomitraphylline, isospeciofoleine, speciofoline, corynoxine A, corynoxeine, and rhynchophylline) in US-grown kratom plants and commercial products. These commercial products shared a qualitatively similar alkaloid profile, with 12 – 13 detected alkaloids and high levels of the indole alkaloid mitragynine (13.9 ± 1.1 – 270 ± 24 mg/g). The levels of the other major alkaloids (paynantheine, speciociliatine, speciogynine, mitraciliatine, and isopaynantheine) and the minor alkaloids varied in concentration from product to product. The alkaloid profile of US-grown M. speciosa "Rifat" showed high levels of the indole alkaloid speciogynine (7.94 ± 0.83 – 11.55 ± 0.18 mg/g) and quantifiable levels of isomitraphylline (0.943 ± 0.033 – 1.47 ± 0.18 mg/g). Notably, the alkaloid profile of a US-grown M. speciosa seedling was comparable to the commercial products with a high level of mitragynine (15.01 ± 0.20 mg/g). This work suggests that there are several M. speciosa chemotypes. [ABSTRACT FROM AUTHOR]

Many consumers are turning to kratom (Mitragyna speciosa) to self-manage pain and opioid addiction. In the United States, an array of capsules, powders, and loose-leaf kratom products are readily available. Additionally, several online sites supply live kratom plants. A prerequisite to establishing quality control and quality assurance standards for the kratom industry, or understanding how alkaloid levels effect clinical outcomes, is the identification and quantitation of major and minor alkaloid constituents within available products and preparations. To this end, an ultra-high performance liquid chromatography-high resolution mass spectrometry method was developed for the analysis of 8 indole alkaloids (7-hydroxymitragynine, ajmalicine, paynantheine, mitragynine, speciogynine, isopaynantheine, speciociliatine, and mitraciliatine) and 6 oxindole alkaloids (isomitraphylline, isospeciofoleine, speciofoline, corynoxine A, corynoxeine, and rhynchophylline) in US-grown kratom plants and commercial products. These commercial products shared a qualitatively similar alkaloid profile, with 12 – 13 detected alkaloids and high levels of the indole alkaloid mitragynine (13.9 ± 1.1 – 270 ± 24 mg/g). The levels of the other major alkaloids (paynantheine, speciociliatine, speciogynine, mitraciliatine, and isopaynantheine) and the minor alkaloids varied in concentration from product to product. The alkaloid profile of US-grown M. speciosa "Rifat" showed high levels of the indole alkaloid speciogynine (7.94 ± 0.83 – 11.55 ± 0.18 mg/g) and quantifiable levels of isomitraphylline (0.943 ± 0.033 – 1.47 ± 0.18 mg/g). Notably, the alkaloid profile of a US-grown M. speciosa seedling was comparable to the commercial products with a high level of mitragynine (15.01 ± 0.20 mg/g). This work suggests that there are several M. speciosa chemotypes. [ABSTRACT FROM AUTHOR]

Kratom, a tropical plant native to Southeast Asia, has become a $1 billion industry in the US. While it has been used for centuries in Southeast Asia for its pain-relieving and mood-boosting properties, there is limited research to support these claims. Kratom can act as a stimulant or a sedative depending on the dosage, and its main chemical components give it its effects. The safety of kratom is still being studied, but consuming it in concentrated forms can be dangerous. The FDA has warned against the use of kratom due to potential health risks, including liver damage and seizures. Kratom's legal status varies by state, with some states banning it completely and others passing laws to regulate its sale. The FDA is currently conducting studies on kratom to evaluate its safety and abuse potential. [Extracted from the article]

Research conducted at George Washington University has found that there are disparities in the associations between opioid and kratom use in the United States based on race/ethnicity and sexual orientation. The study used data from a nationally representative survey and found that opioid use was positively associated with kratom use, but these associations were weaker among non-Hispanic Black and Hispanic participants compared to non-Hispanic White participants. Among those reporting past-year opioid use, misuse and use disorder were also positively associated with kratom use. The researchers suggest that further investigation is needed to understand the mechanisms behind these differences and inform prevention and intervention efforts. [Extracted from the article]

Kratom, a herbal supplement derived from a tropical tree in Southeast Asia, has gained popularity in the US over the past decade. The US Drug Enforcement Agency states that kratom can act as a stimulant or sedative and warns of its potential for addiction. While the FDA advises against its use, kratom remains legal in most states and is widely available. The industry promotes kratom as a wellness product and a way to overcome addiction, but lawsuits alleging hospitalizations and deaths related to its use are increasing. Experts express concerns about kratom's lack of regulation and potential for abuse, despite its potential to help users with drug addiction. The death toll associated with kratom is relatively small compared to the opioid epidemic, but the industry argues that many deaths involved other substances or causes. The weak nature of kratom's effects may lead some users to take more than the recommended amount, increasing the risk of addiction. While some support further research into kratom's efficacy in treating opioid abuse, others accuse the industry of exploiting those already suffering from addiction. [Extracted from the article]

The article focuses on the assessment, diagnosis, and treatment of Kratom Use Disorder (KUD) in the context of current clinical research. Topics include the application of DSM-5 criteria to KUD, differences between KUD and other substance use disorders, and the current challenges and controversies in diagnosing and treating KUD.

This article from Reactions Weekly describes two case reports of neonatal abstinence syndrome (NAS) in male neonates who were exposed to mitragyna-speciosa (Kratom) in utero. In the first case, the neonate's mother had a history of substance use, including mitragyna-speciosa, and the neonate exhibited symptoms such as hypertonia and inconsolable crying. Methadone was used to treat the NAS, and the neonate was eventually discharged. In the second case, the neonate's mother reported using mitragyna-speciosa to stay away from heroin, and the neonate developed symptoms such as hypertonia and jitteriness. Methadone was also used to treat the NAS, and the neonate was discharged after successful treatment. The article suggests that NAS can occur due to in-utero exposure to mitragyna-speciosa. [Extracted from the article]

Journalists from the Los Angeles Times and Tampa Bay Times conducted investigations into drug-related issues and created novel datasets to reveal important information. The Los Angeles Times journalists investigated the sale of counterfeit pills containing dangerous substances in Mexican pharmacies, using laboratory testing and data compilation to uncover the extent of the problem. Their reporting led to significant impact, including warnings from the State Department and law enforcement actions in Mexico. The Tampa Bay Times journalists focused on the use of kratom, a psychoactive herb, and built their own datasets to analyze deaths related to kratom use in Florida. Their investigation also involved purchasing and testing kratom products and analyzing import data. Both investigations demonstrate the power of creating one's own dataset to uncover important information and drive impactful reporting. [Extracted from the article]

Kratom ka-boom; what a sport; treed; and other highlights of recent tax cases. [ABSTRACT FROM AUTHOR]

The US Food and Drug Administration (FDA) has issued a warning to consumers about a kratom product called OPMS Black Liquid Kratom, which has been linked to a death. Kratom is a plant-extract drink that is used to boost energy levels and relieve pain, but it can be addictive and have serious health effects. The FDA has not approved any drug products containing kratom and has concerns about its use in supplements and foods. The maker of the product, Optimized Plant Mediated Solutions, has been sued by parents whose son died after using it. The FDA's announcement has been met with surprise and will be challenged by the company. [Extracted from the article]

Researchers at the University of Kansas have published a study on the use of plasma exchange to treat severe jaundice and liver failure caused by kratom use. Kratom is an herbal supplement known for its stimulating properties and pain reduction effects. The study describes the case of a 56-year-old man who experienced liver failure after taking kratom. Plasma exchange, an unconventional therapy, was performed and resulted in a significant improvement in the patient's condition. This is the first reported case of reversing kratom poisoning using plasma exchange. [Extracted from the article]

A report from San Diego State University discusses research findings on the use of kratom, a bioactive product derived from a tree in Southeast Asia. The study collected data from Reddit posts to examine the motivations, effects, and consequences associated with kratom use. The research found that while many users reported benefits from kratom, there were also negative experiences that have not been well-documented in surveys. The study suggests that more research and detailed product information are needed to inform consumer decision-making. [Extracted from the article]

A recent study conducted by Pinney Associates Inc. explores the safety and toxicology of kratom in the context of public health. Kratom, a substance with diverse and complex pharmacology, has gained popularity in the United States in recent years. The study provides an integrated update on the benefits, risks, pharmacology, and epidemiology of kratom, aiming to inform regulation and policy. The research concludes with recommendations for federal oversight and research priorities to address current knowledge gaps. This study serves as a valuable resource for understanding kratom and guiding future scientific studies and regulatory efforts. [Extracted from the article]

A case report from the University Sains Malaysia discusses the use of opioids in treating a patient with kratom use disorder. Kratom is a botanical plant product used for pain relief and fatigue, but it can also be addictive. The 26-year-old patient sought treatment due to withdrawal effects and financial costs. The treatment involved buprenorphine-naloxone (suboxone) in pill form, along with non-pharmacological interventions such as psychoeducation, psychotherapy, and motivational interviews. The patient successfully became kratom-free within a week of treatment. [Extracted from the article]

Researchers from Midwestern University College of Pharmacy in Glendale, Arizona, have discussed the potential use of kratom as a harm reduction agent for substance use disorders. Kratom is an herbal substance that can produce opioid and stimulant-like effects and has been historically used for this purpose in Southeast Asia. The researchers highlight the need for expanded treatment options for patients with substance use disorders and describe the pharmacology and early pre-clinical research on kratom's therapeutic potential. However, they also acknowledge concerns about adverse effects, dependence risk, and limited regulation of kratom. Further research is needed to fully understand its benefits and risks. [Extracted from the article]

A recent preprint abstract discusses the potential for using yeast to produce kratom monoterpene indole alkaloids (MIAs), such as mitragynine and speciogynine, which have shown promise as opioid receptor ligands for pain, addiction, and depression treatment. The researchers reconstructed a synthetic pathway in Saccharomyces cerevisiae to produce these compounds from a common MIA precursor. Through optimization, they achieved a high titer of approximately 290 g/L of kratom MIAs from glucose. The study also explored the production of fluorinated and hydroxylated mitragynine derivatives with potential applications in drug discovery. This research introduces a yeast cell factory platform for the biomanufacturing of complex natural and new-to-nature kratom MIAs derivatives with therapeutic potential. [Extracted from the article]

Mitragynine is the most abundant psychoactive alkaloid derived from the leaves of Mitragyna speciosa (kratom), a tropical plant indigenous to regions of Southeast Asia. Mitragynine displays a moderate affinity to opioid receptors, and kratom is often self-prescribed to treat pain and/or opioid addiction. The purpose of this study was to investigate the safety and pharmacokinetic properties of mitragynine in the dog. Single dose oral (5 mg/kg) and intravenous (0.1 mg/kg) pharmacokinetic studies of mitragynine were performed in female beagle dogs. The plasma concentrations of mitragynine were measured using ultra-performance liquid chromatography coupled with a tandem mass spectrometer, and the pharmacokinetic properties were analyzed using non-compartmental analysis. Following intravenous administration, mitragynine showed a large volume of distribution (Vd , 6.3 ± 0.6 L/kg) and high clearance (Cl, 1.8 ± 0.4 L/h/kg). Following oral mitragynine dosing, first peak plasma (Cmax , 278.0 ± 47.4 ng/mL) concentrations were observed within 0.5 h. A potent mu-opioid receptor agonist and active metabolite of mitragynine, 7-hydroxymitragynine, was also observed with a Cmax of 31.5 ± 3.3 ng/mL and a Tmax of 1.7 ± 0.6 h in orally dosed dogs while its plasma concentrations were below the lower limit of quantification (1 ng/mL) for the intravenous study. The absolute oral bioavailability of mitragynine was 69.6%. Administration of mitragynine was well tolerated, although mild sedation and anxiolytic effects were observed. These results provide the first detailed pharmacokinetic information for mitragynine in a non-rodent species (the dog) and therefore also provide significant information for allometric scaling and dose predictions when designing clinical studies. [ABSTRACT FROM AUTHOR]

A recent study conducted at Thomas Jefferson University in Philadelphia examined the pharmacokinetics of mitragynine and 7-hydroxymitragynine, two alkaloids found in kratom leaves. The study involved a dose-escalation study of dried kratom leaf powder, with mitragynine concentrations increasing proportionally to the dose. The study found that steady-state concentrations of mitragynine were reached within 8-9 days, while steady-state concentrations of 7-hydroxymitragynine were reached within 7 days. The research provides valuable information for future clinical dosing studies and the interpretation of clinical and forensic concentrations of mitragynine and 7-hydroxymitragynine. [Extracted from the article]

A recent report from the University of Florida discusses the pharmacokinetic interaction between kratom and cannabidiol (CBD) in male rats. Kratom and CBD products are commonly used to self-treat conditions such as anxiety, pain, and mood elevation. The study found that when CBD was administered alongside kratom, there was a significant increase in the exposure of mitragynine, the most abundant alkaloid in kratom, as well as other minor alkaloids. This suggests that coadministration of CBD may delay and enhance the effects of kratom. Further research is needed to fully understand the implications of this interaction. [Extracted from the article]

A recent study conducted by the National Institute on Drug Abuse Intramural Research Program examined the use of kratom, a legal substance in the US that contains opioid-like compounds. The study used ecological momentary assessment (EMA) to gather real-time data on kratom use, effects, and motivations among US adults. The findings showed that most participants used kratom in a nonproblematic way, with withdrawal avoidance being a key motivator when problematic use occurred. The study suggests the need for longitudinal studies to understand changes in kratom use patterns and effects over time. [Extracted from the article]

The U.S. Food and Drug Administration oversaw the recall and destruction of a large volume of kratom-containing products manufactured and distributed nationwide under the brand names Botany Bay, Enhance Your [...]

Kratom (Mitragyna speciosa) has been examined for its opioid activity, especially for the treatment of opioid withdrawal and pain. Mitragynine, the most abundant alkaloid in kratom, is thought to be the major psychoactive alkaloid. An HPLC method was developed for the quantification of mitragynine in kratom leaf extracts. In addition, a multiple reaction mode based UPLC-MS/MS method was developed and validated for the quantification of mitragynine in rat plasma. Pharmacokinetic studies were performed by comparing a single intravenous dose of mitragynine (5 mg/kg, mitragynine hydrochloride) to a single oral dose of mitragynine (20 mg/kg, mitragynine hydrochloride), lyophilized kratom tea, and the organic fraction of the lyophilized kratom tea at an equivalent mitragynine dose of 20 mg/kg in rats. After intravenous administration, mitragynine exhibited a biexponential decrease in the concentration-time profile, indicating the fast distribution of mitragynine from the systemic circulation or central compartment to the peripheral compartments. Mitragynine hydrochloride, lyophilized kratom tea, and the lyophilized kratom tea organic fraction were dosed orally and the absolute oral bioavailability of mitragynine in rats was found to be 1.5- and 1.8-fold higher than that of mitragynine dosed alone. The results provide evidence that an equivalent oral dose of the traditional preparation (lyophilized kratom tea) and formulated/manufactured products (organic fraction) of kratom leaves provide better systemic exposure of mitragynine than that of mitragynine dosed alone. [ABSTRACT FROM AUTHOR]

A recent study conducted by Auburn University aimed to assess the awareness and knowledge of kratom among pharmacists in Alabama. The study found that approximately 50% of the 257 participants had heard of kratom, with males and pharmacists working for independent pharmacies more likely to be aware of it. However, only 14% of those who had heard of kratom considered themselves knowledgeable about it, and only 44% knew that it was illegal in Alabama. These findings suggest a need for further education on kratom among community pharmacists in Alabama. [Extracted from the article]

A recent report from the University of Florida explores the use of kratom tea bag preparations and their reported pharmacological effects. Kratom, a plant native to Southeast Asia, has gained popularity as an herbal supplement in Western countries. The study found that kratom tea bag samples had lower levels of mitragynine, a key alkaloid, compared to other kratom products. However, consumers of kratom tea bags still reported beneficial effects, suggesting that tea infusions may provide a potentially safer formulation. Overall, this research provides insights into the use of kratom and its potential health benefits. [Extracted from the article]

A new report from Walailak University in Thailand examines the neuropharmacological effects of kratom, a plant that has been considered a narcotic drug in many parts of the world. The researchers found that kratom contains almost fifty pure compounds, with the most prevalent compounds, mitragynine and 7-hydroxy mitragynine, displaying morphine-like effects on human opioid receptors. The study also highlights kratom's potential therapeutic benefits for neurological disorders, as well as its anti-inflammatory, antioxidative, antibacterial, and gastroprotective effects. The research aims to resolve ambiguities about kratom's neuronal effects and its prospects as a therapeutic target. [Extracted from the article]

A study conducted in the United States found that adults who use kratom, a plant that produces opioid-like effects, have poorer psychological health, higher rates of chronic pain, and higher rates of substance use disorder compared to those who do not use kratom. The study also found that kratom users were typically younger, male, unpartnered, and had lower income. The strongest predictors of kratom use were the use of other drugs, such as cannabidiol, psychedelics, and nonmedical prescription opioids. Despite these findings, the study suggests that the use of other substances may be the strongest indicators of kratom use. [Extracted from the article]

A case study published in Reactions Weekly reports on a neonate who developed neonatal abstinence syndrome (NAS) after being exposed to Mitragyna speciosa (Kratom) in utero. The mother had been taking oral Kratom daily during her pregnancy. The neonate was found to have NAS and serum analysis confirmed the presence of mitragynine. The neonate was successfully treated with phenobarbital. This case highlights the potential risks associated with Kratom use during pregnancy and the need for further research in this area. [Extracted from the article]

This article provides information on kava and kratom, two plant-based drinks that are sold in bars as non-alcoholic alternatives. While they may be found in similar places, kava and kratom are unrelated substances. Kratom, in particular, carries a higher risk for addiction and can have opioid-like properties in higher doses. The effects of kratom are still not fully understood, and it has been associated with addiction, liver toxicity, and cardiovascular toxicity. Kava, on the other hand, is an extract made from a plant called Piper methysticum and has been used for centuries in the South Pacific. While there are some risks associated with kava, such as potential liver toxicity when used with certain substances, long-term liver damage has not been found in historical use. The reasons for pairing kratom and kava in bars are unclear. [Extracted from the article]

Kratom, a drink extracted from a plant native to Southeast Asia, has gained popularity in the US as an alcohol alternative. However, it can have addictive, opioid-like properties and has been associated with fatal overdoses. While some states are trying to regulate kratom, there has been little federal regulatory action. The kratom lobbying group is advocating for limited regulations to keep it on the market, while some lawmakers are taking a more critical stance and have banned it altogether. The full effects of kratom are still unknown, and more research is needed to understand its risks and benefits. [Extracted from the article]

2020 FEB 8 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Heart Disorders and Diseases - Heart Attack. [...]

The New Mon State Party (NMSP) forces destroyed over 300 kratom plants seized at Ngat Pyaw Taw and Sate Kalay villages in Kyarinseikkyi Township, Karen State, earlier this month, MNA [...]

2020 FEB 1 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Opioids. According to news reporting originating in [...]

An outdoor vending machine offering kratom tea, which has psychoactive properties, has raised health concerns in Thailand, according to a Strait Times report. The kratom leaves, according to the U.S. Drug Enforcement Agency, can cause heightened alertness, talkativeness and physical energy. [ABSTRACT FROM AUTHOR]

People who have an allergy or severe sensitivity to tree nuts (coconut) and/or milk, run the risk of serious or life-threatening allergic reaction if they consume this product. Keywords: Allergies; FDA; Food Poisoning; Food Safety; Foodborne Diseases and Conditions; Gastroenterology; Health and Medicine; Immune System Diseases and Conditions; Office of Regulatory Affairs; Risk and Prevention; U.S. Food and Drug Administration EN Allergies FDA Food Poisoning Food Safety Foodborne Diseases and Conditions Gastroenterology Health and Medicine Immune System Diseases and Conditions Office of Regulatory Affairs Risk and Prevention U.S. Food and Drug Administration 71 71 1 10/24/23 20231023 NES 231023 2023 OCT 26 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Summary Company Announcement Date: October 06, 2023 FDA Publish Date: October 06, 2023 Product Type: Food & Beverages Reason for Announcement: Recall Reason Description Undeclared Tree Nut (Coconut) and Milk Company Name: Kula Brands LLC Brand Name: Brand Name(s) Kula Can Product Description: Product Description Pina Colada + Kratom Seltzer Company Announcement Kula Brands LLC is recalling Kula Can - Pina Colada + Kratom Seltzer due to the presence of undeclared tree nuts (coconut) and milk. [Extracted from the article]

As part of a larger study about retail tobacco marketing near colleges, availability of kratom was assessed in summer 2019 in a random sample of 614 vape shops that was stratified to compare stores near (3 miles) and distant (>3 miles) from colleges. The goal of this study was to examine kratom availability in vape shops across the state of California and assess shop compliance with a local kratom sales ban (enacted in 2016) in San Diego City. Keywords: Health and Medicine; Preventive Medicine; Risk and Prevention EN Health and Medicine Preventive Medicine Risk and Prevention 7687 7687 1 10/09/23 20231013 NES 231013 2023 OCT 13 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators publish new report on preventive medicine. [Extracted from the article]

The present finding demonstrated that MG priming in a dose of 10 mg/kg resulted in the reinstatement of morphine-seeking behaviour, whereas the higher MG dose (30 mg/kg) tested suppressed the seeking response. Keywords: Opioids EN Opioids 1651 1651 1 10/03/23 20231006 NES 231006 2023 OCT 6 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on opioids. [Extracted from the article]

The following word combinations were used: kratom and cannabis, kratom and pain, cannabis and pain, kratom and chronic pain, and cannabis and chronic pain. There is sufficient epidemiological evidence to suggest that both kratom and cannabis products are used to self-treat pain, and that some individuals actively use both drugs, which may produce potential additive or synergistic therapeutic benefits that have not yet been characterized." Keywords: Philadelphia; State:Pennsylvania; United States; North and Central America; Cannabinoids; Chronic Pain; Drugs and Therapies; Epidemiology; Health and Medicine; Hydrocarbons; Marijuana/Cannabis; Musculoskeletal Diseases and Conditions; Neurologic Manifestations; Pain; Terpenes; Tetrahydrocannabinol; Therapy EN Philadelphia State:Pennsylvania United States North and Central America Cannabinoids Chronic Pain Drugs and Therapies Epidemiology Health and Medicine Hydrocarbons Marijuana/Cannabis Musculoskeletal Diseases and Conditions Neurologic Manifestations Pain Terpenes Tetrahydrocannabinol Therapy 1877 1877 1 08/28/23 20230829 NES 230829 2023 AUG 28 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators discuss new findings in Marijuana/Cannabis - Tetrahydrocannabinol. [Extracted from the article]

Keywords: Analgesics; Antidotes; Buprenorphine Therapy; Central Nervous System Agents; Drugs and Therapies; Health and Medicine; Naloxone Therapy; Narcotic Analgesics; Narcotic Antagonist; Opioids; Pharmaceuticals; Telemedicine EN Analgesics Antidotes Buprenorphine Therapy Central Nervous System Agents Drugs and Therapies Health and Medicine Naloxone Therapy Narcotic Analgesics Narcotic Antagonist Opioids Pharmaceuticals Telemedicine 1851 1851 1 08/14/23 20230820 NES 230820 2023 AUG 18 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- A new study on opioids is now available. Literature searches reveal recommendations to use buprenorphine (or buprenorphine-naloxone), which are medications to treat opioid use disorder, in order to treat patients with kratom use disorder; however, there are no formal guidelines available. [Extracted from the article]

He attempted multiple times to decrease the use, but each attempt caused too much discomfort (drug-withdrawal and drug-dependence). He attempted multiple times to decrease the use for about 5 years, but each attempt caused too much discomfort (drug-withdrawal and drug-dependence). [Extracted from the article]

As the opioid epidemic continues to ravage the United States, patients and physicians are looking for less-addictive alternatives for pain control. For a growing number of U.S. patients, top among [...]

The article discusses scientists' efforts to develop new drugs to treat pain as a replacement for opioids, including in regard to preventing opioid addiction, the use of marijuana to treat pain and the U.S.'s drug policy towards the opioid supplement Kratom. An overview of opioid receptors in the base of the brain, including the binding of morphine to the opioid receptors, is provided.

Keywords: Temple; State:Texas; United States; North and Central America; Opioids EN Temple State:Texas United States North and Central America Opioids 1728 1728 1 07/03/23 20230707 NES 230707 2023 JUL 7 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Opioids. The news editors report that additional information may be obtained by contacting Emily H. Garmon, Texas A&M University Hlth Sci Ctr, Baylor Scott & White Temple Dept Anesthesiol, College of Medicine, Temple, TX, United States. [Extracted from the article]

Keywords: Auburn; State:Alabama; United States; North and Central America; Central Nervous System; Health and Medicine; Opioids; Pharmaceuticals; Pharmacology; Risk and Prevention EN Auburn State:Alabama United States North and Central America Central Nervous System Health and Medicine Opioids Pharmaceuticals Pharmacology Risk and Prevention 917 917 1 06/12/23 20230616 NES 230616 2023 JUN 16 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Investigators discuss new findings in Opioids. Kratom induces analgesia and mild euphoria, with a lower risk of respiratory depression or adverse central nervous system effects compared to traditional opioid medications. [Extracted from the article]

Keywords: New York City; State:New York; United States; North and Central America; Opioids; Risk and Prevention EN New York City State:New York United States North and Central America Opioids Risk and Prevention 743 743 1 05/22/23 20230526 NES 230526 2023 MAY 26 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Current study results on Opioids have been published. Keywords for this news article include: New York City, New York, United States, North and Central America, Opioids, Risk and Prevention, New York University (NYU). [Extracted from the article]

Keywords: Baltimore; State:Maryland; United States; North and Central America; Opioids EN Baltimore State:Maryland United States North and Central America Opioids 977 977 1 05/22/23 20230526 NES 230526 2023 MAY 26 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Research findings on Opioids are discussed in a new report. Keywords for this news article include: Baltimore, Maryland, United States, North and Central America, Opioids, National Institute of on Drug Abuse Intramural Research Program. [Extracted from the article]

Keywords for this news article include: National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland, United States, North and Central America, Pharmacology, Drugs and Therapies. Keywords: Drugs and Therapies; Pharmacology EN Drugs and Therapies Pharmacology 1083 1083 1 05/22/23 20230523 NES 230523 2023 MAY 22 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators discuss new findings in pharmacology. [Extracted from the article]

Keywords for this news article include: Spokane, Washington, United States, North and Central America, Drugs and Therapies, Opioids, Washington State University. Keywords: Spokane; State:Washington; United States; North and Central America; Drugs and Therapies; Opioids EN Spokane State:Washington United States North and Central America Drugs and Therapies Opioids 1773 1773 1 05/15/23 20230519 NES 230519 2023 MAY 19 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Opioids. Spokane, State:Washington, United States, North and Central America, Drugs and Therapies, Opioids. [Extracted from the article]